Anatara Lifesciences Ltd Stock

Equities

ANR

AU000000ANR0

Pharmaceuticals

Delayed Australian S.E. 10:23:51 2024-04-25 pm EDT 5-day change 1st Jan Change
0.046 AUD 0.00% Intraday chart for Anatara Lifesciences Ltd +17.95% +109.09%
Sales 2022 - Sales 2023 - Capitalization 3.36M 2.19M
Net income 2022 -2M -1.3M Net income 2023 -2M -1.3M EV / Sales 2022 -
Net cash position 2022 1.1M 720K Net cash position 2023 401K 262K EV / Sales 2023 -
P/E ratio 2022
-1.54 x
P/E ratio 2023
-1.35 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 40.35%
More Fundamentals * Assessed data
Dynamic Chart
1 week+17.95%
Current month+17.95%
1 month+6.98%
3 months+119.05%
6 months+43.75%
Current year+109.09%
More quotes
1 week
0.04
Extreme 0.036
0.05
1 month
0.03
Extreme 0.034
0.05
Current year
0.02
Extreme 0.021
0.05
1 year
0.02
Extreme 0.021
0.05
3 years
0.02
Extreme 0.021
0.19
5 years
0.02
Extreme 0.021
0.50
10 years
0.02
Extreme 0.021
1.83
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 19-01-22
Chief Operating Officer - -
Corporate Officer/Principal - 21-12-05
Members of the board TitleAgeSince
Chief Executive Officer 63 19-01-22
Chief Operating Officer - -
Director/Board Member - -
More insiders
Date Price Change Volume
24-04-25 0.046 0.00% 20 000
24-04-24 0.046 +6.98% 111,942
24-04-23 0.043 +2.38% 22,046
24-04-22 0.042 +7.69% 1,130,501
24-04-19 0.039 -7.14% 510,000

Delayed Quote Australian S.E., April 25, 2024 at 10:23 pm EDT

More quotes
Anatara Lifesciences Ltd is an Australia-based life sciences company. The Company is engaged in developing evidence-based solutions for gastrointestinal diseases in humans and animals. Its products include Gastrointestinal ReProgramming (GaRP), Detach, BONIFF, and ANR-pf. Its GaRP Product is a microbiome-targeted multi-component complementary medicine, which is designed to address the primary underlying factors associated with chronic gastrointestinal conditions, such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Detach is a non-antibiotic approach to aid in the control of diarrheal disease known as scour, which is developed using bromelain. BONIFF is a revised formulation which is applied to dry feed for piglets after weaning, reducing labor input, and simplifying the entire process. ANR-pf is an enriched formulation for poultry in water, designed to allow the full delivery of key additives in a quick and flexible dosing method.
More about the company